KRISTI KIMBLER: Open Payments
NPI 1164081303 · NEWNAN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$710 in 28 payments from 13 companies in 2025. Trend: 2023 $168 · 2024 $287 · 2025 $710
Food & beverage: $576Education: $134
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $131 |
| Mallinckrodt Hospital Products Inc. | 2 | $120 |
| Novartis Pharmaceuticals Corporation | 3 | $69 |
| Ardelyx, Inc. | 3 | $67 |
| Calliditas Therapeutics US Inc. | 2 | $57 |
| Travere Therapeutics, Inc. | 3 | $48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47 |
| Novo Nordisk Inc | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Aurinia Pharma U.S., Inc. | 2 | $31 |
Products named: ACTHAR, FARXIGA, Fabhalta, IBSRELA, TARPEYO, JARDIANCE, Ozempic, JYNARQUE.
Industry payments across GA — which companies pay providers there.
